# Junta clínica — PT-pseudo_fa4a71ae9a34 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_fa4a71ae9a34",
  "pid": "PT-pseudo_fa4a71ae9a34",
  "task": 1,
  "psa": 4.8,
  "age": 65,
  "months": 2,
  "pirads": "5",
  "psad": 0.19,
  "psav": 1.05,
  "psap": 3.6,
  "vol": 25.31,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.8035576,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 4.8 ng/mL. PI-RADS 5. PSAD 0.19. Prostate volume 25 mL. DRE nodus. csPCa 0.80.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "90 kg",
    "height": "176 cm",
    "bmi": "29.1",
    "bp": "129/75 mmHg",
    "hr": "56 bpm",
    "smoking": "Non-smoker",
    "last_dental": "1 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "01 Feb 2025",
  "enc_ref": "Dr. H. Martens (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Rising prostate-specific antigen (4.8 ng/mL) combined with a confirmed ISUP GG 4 result from a previous biopsy procedure."
    },
    {
      "s": "History",
      "t": "Investigated initially for an incidental prostate-specific antigen elevation in the middle of 2023, this 65-year-old individual subsequently received a positive biopsy result confirming ISUP GG 4 disease. He works as a retired carpenter, resides with his partner, and reports being never married. A non-smoker with no active medications or comorbid conditions, he maintains a regular cycling regimen five days weekly and restricts alcohol to four units per week. Lower urinary tract symptoms remain minimal, reflected by an International Prostate Symptom Score of 3 out of 35, and he explicitly denies hematuria or pelvic discomfort. His clinical background is otherwise unremarkable aside from a recent dermatology visit for actinic keratosis screening. Commuting over an hour by train, he favors flexible scheduling to accommodate his travel routine."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: firm, discrete nodule palpable in the right lobe; mobility: unrestricted; asymmetry: noted only at the nodular site, with the remainder of the gland presenting symmetrically and smooth. Vital parameters demonstrate stability, registering a blood pressure of 129/75 mmHg and a heart rate of 56 bpm. Systemic inspection reveals no palpable lymphadenopathy or abdominal abnormalities."
    }
  ],
  "occupation": "retired carpenter",
  "marital": "Never married",
  "living": "Lives with partner",
  "next_of_kin": "Sibling (sister)",
  "recent_other": [
    "Dermatology — actinic keratosis check"
  ],
  "alcohol": "4 units / week",
  "exercise": "Cycling 5x/week (commuter)",
  "ipss": "IPSS score: 3/35 (mild LUTS)",
  "admin": "Patient travels 60+ min by train to clinic; allow buffer.",
  "mri_hospital": "Catharina Ziekenhuis (Eindhoven)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_fa4a71ae9a34
Task: 1

Encounter: Urology - outpatient on 01 Feb 2025.
Referrer: Dr. H. Martens (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 65-year-old male
  - PSA: 4.8 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.19 ng/mL²
  - PSA velocity: 1.05 ng/mL/yr
  - Prior PSA: 3.6 ng/mL
  - Prostate volume: 25.31 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8035576 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 4.8 ng/mL. PI-RADS 5. PSAD 0.19. Prostate volume 25 mL. DRE nodus. csPCa 0.80.

Vitals: weight 90 kg, height 176 cm, BMI 29.1, BP 129/75 mmHg, HR 56 bpm. Smoking: Non-smoker.

Chief complaint: Rising prostate-specific antigen (4.8 ng/mL) combined with a confirmed ISUP GG 4 result from a previous biopsy procedure.

History: Investigated initially for an incidental prostate-specific antigen elevation in the middle of 2023, this 65-year-old individual subsequently received a positive biopsy result confirming ISUP GG 4 disease. He works as a retired carpenter, resides with his partner, and reports being never married. A non-smoker with no active medications or comorbid conditions, he maintains a regular cycling regimen five days weekly and restricts alcohol to four units per week. Lower urinary tract symptoms remain minimal, reflected by an International Prostate Symptom Score of 3 out of 35, and he explicitly denies hematuria or pelvic discomfort. His clinical background is otherwise unremarkable aside from a recent dermatology visit for actinic keratosis screening. Commuting over an hour by train, he favors flexible scheduling to accommodate his travel routine.

Physical examination: DRE — texture: firm, discrete nodule palpable in the right lobe; mobility: unrestricted; asymmetry: noted only at the nodular site, with the remainder of the gland presenting symmetrically and smooth. Vital parameters demonstrate stability, registering a blood pressure of 129/75 mmHg and a heart rate of 56 bpm. Systemic inspection reveals no palpable lymphadenopathy or abdominal abnormalities.

Patient info: retired carpenter; Never married; Lives with partner.
Next of kin: Sibling (sister).

Lifestyle: alcohol 4 units / week; exercise Cycling 5x/week (commuter); IPSS score: 3/35 (mild LUTS).

Recent other appointments: Dermatology — actinic keratosis check.
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.55
  uncertainty  +/- 0.10 epistemic (95% band 0.35-0.75); among patients I cannot tell apart the outcome was 0.99 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.61: PI-RADS 5, PSA 6.9, PSAD 0.257, age 67, DRE Nodus -> BIOPSY (uncertain). He wrote: "What was the result of the earlier positive biopsy and the MRI precluding that biopsy? Hard to determine what we are looking at here."
  2. distance 0.71: PI-RADS 5, PSA 6.9, PSAD 0.171, age 67, DRE Nodus -> DEFER (borderline). He wrote: "Need to know if the P5 lesion has grown in size. If not no biopsy."
  3. distance 0.81: PI-RADS 5, PSA 8.3, PSAD 0.215, age 66, DRE Suspicious -> DEFER (clear). He wrote: "This person should discuss curative treatment (younger patient with palpable, MRI-visible high-risk disease incl Gleason 5 findings). If not curative treatment for any r…"

PRECEDENT: DEFER (weighted vote 0.38 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a repeat biopsy on MRI is mandated to confirm histological progression before a change in treatment strategy. A stable MRI (PRECISE 1-3) does not make repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable PSA-D < 0.15.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not decisive because the guideline makes the decision dependent on the MRI findings, which are not yet fully established. The precedent suggests that the decision hinges on the documented grade of the prior biopsy and the surveillance history, which is what the cohort criterion focuses on.

WHAT WE STILL NEED
The prior biopsy result is documented as "Positive" on the panel, which is a fact that the guideline makes decisive.
The documented grade of the prior biopsy (ISUP GG 4) is known, which is a fact that the guideline makes decisive.
The number of biopsy sessions and their dates is not known, which is a fact that the guideline makes decisive.
Whether he is on a surveillance protocol with a confirmatory biopsy due is not known, which is a fact that the guideline makes decisive.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on establishing the documented grade and surveillance status from the previous notes, as the guideline requires this information to determine the need for a repeat biopsy.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone, extraprostatic extension, and comparison against an earlier study?
  psa_trend (get_psa_trend) -> What is the serial PSA value trend (rising, flat, or falling)?
  previous_notes (get_previous_notes) -> What was the prior biopsy result (Gleason/ISUP), the number and dates of biopsy sessions, and whether he is on a surveillance protocol with a confirmatory biopsy due?
  laboratory_results (get_lab_results) -> What are the full panel results, including free-PSA fraction, renal function, and haemoglobin?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What was the documented grade (Gleason or ISUP) of the prior biopsy?
  Q2. What is the number and date of previous biopsy sessions, and is the patient on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The lesion size is roughly 12 mm in the right peripheral zone. Extraprostatic extension is not mentioned. Comparison against an earlier study is "new".
psa_trend
The serial PSA value trend is rising, with values at "Jun 2023" of "1.2 ng/mL", "Dec 2023" of "4.6 ng/mL", "Jul 2024" of "3.6 ng/mL", and "Feb 2025" of "4.8 ng/mL".
previous_notes
The prior biopsy result was "Positive" (ISUP GG 4 is implied by the initial note). There are two documented biopsy sessions: one on "06 Jun 2024" and another on "11 Aug 2023". The notes do not explicitly state if the patient is on a surveillance protocol with a confirmatory biopsy due.
laboratory_results
The full panel results show PSA as "4.8 ng/mL" on "15 Jan 2025", Free PSA as "0.54 ng/mL", and %Free PSA as "11%". Renal function is stable with Creatinine at "101 umol/L" and eGFR ">60 mL/min/1.73m2".

WHAT I DID NOT OPEN
family-history of prostate cancer (anamnesis) because the previous notes provided sufficient information regarding the prior biopsy status and surveillance context.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS 5 designation on the MRI.
Rising PSA trend from 3.6 ng/mL to 4.8 ng/mL.
The EAU guideline states a repeat biopsy is mandated to confirm histological progression.
Findings that argue AGAINST sampling this patient now:
The prior biopsy result is documented as "Positive".
The previous notes do not explicitly state the patient is on a surveillance protocol with a confirmatory biopsy due.

WHERE THIS LEANS
The combination of a PI-RADS 5 finding and a rising PSA trend strongly supports the need for further histological confirmation as per the EAU guideline.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 4.80 ng/mL over 4 points spanning 20 months; velocity +1.71 ng/mL per year; doubling time about 12 months.
PROJECTION at 6 months: 7.2 ng/mL, conformal 95% band 2.1-25.1.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.52
  uncertainty  +/- 0.08 epistemic (95% band 0.37-0.67), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.55  ('discuss' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.52  ('discuss' tier, fusion_full)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.38  (k=3 precedents)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.51 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('discuss' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.
Dissenting on the board: EXPERT-LIBRARY. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—radiology_report, psa_trend, previous_notes, and laboratory_results—directly address the moderator's questions regarding the prior biopsy grade and surveillance status.

ALIGNMENT WITH THE PANEL
The panel protocol concluded with a weighted vote for BIOPSY, driven by EXPERT-STRUCTURED and EXPERT-FUSION, despite the lack of a documented prior grade in the opened documents.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What was the documented grade (Gleason or ISUP) of the prior biopsy? The previous_notes state the result was "Positive" (ISUP GG 4 is implied by the initial note), but the specific grade is not explicitly stated in the retrieved text.
Q2. What is the number and date of previous biopsy sessions, and is the patient on a surveillance protocol with a confirmatory biopsy due? The previous_notes state there were two sessions (06 Jun 2024 and 11 Aug 2023), but it does not explicitly state if he is on a surveillance protocol with a confirmatory biopsy due.

WHAT CARRIES WEIGHT, AND WHY
The rising PSA trend (from 3.6 to 4.8 ng/mL) and the PI-RADS 5 designation on the MRI are highly relevant as they support the need for further histological confirmation, aligning with the EAU guideline. The lack of explicit surveillance status in the notes is a critical missing piece for the guideline application.

MY SUGGESTION TO THE CHAIR
Given the rising PSA trend and the PI-RADS 5 finding, which support the EAU mandate for confirmation of progression, I suggest proceeding with a biopsy to establish the current histological status. This should be done with a firm recommendation based on the clinical trajectory.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Given the PI-RADS 5 designation on the MRI and the rising PSA trend from 3.6 to 4.8 ng/mL, a repeat biopsy is indicated to confirm histological progression as per EAU guidelines. The lack of an explicitly documented prior biopsy grade in the retrieved notes necessitates further histological confirmation. The evidence converged on the need for sampling due to the combination of high-risk imaging and biochemical progression.

What carried weight: bx=important, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
